Stocks · News reference
Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug
Artelo Biosciences shares new nonclinical data showing its oral cannabinoid drug ART27.13 matches semaglutide weight loss in obese mice.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Artelo Biosciences Says ART27.13 Cut Body Weight About 20% In Obese Mice, Matching Semaglutide; Combination With Semaglutide Produced About 40% Weight Loss
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Novo Nordisk, Anthropic Team Up For AI Drug Research
Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement responsible data governance standards.
Novo Nordisk Announces Collaboration With Anthropic To Use Claude Science And Anthropic Models For Drug Discovery, Software Development
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916768
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.